AQST
Aquestive Therapeutics, Inc.NASDAQHealthcare$4.13+0.00%ClosedMarket Cap: $410.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-14.82
P/S
9.12
EV/EBITDA
-6.44
DCF Value
$-2.25
FCF Yield
-13.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
58.3%
Operating Margin
-159.5%
Net Margin
-188.1%
ROE
195.7%
ROA
-52.2%
ROIC
-57.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $13.0M | 55.2% | $-28.8M | $-31.9M | $-0.26 | — |
| FY 2025 | $44.5M | 58.3% | $-71.1M | $-83.8M | $-0.76 | — |
| Q3 2025 | $12.8M | 64.8% | $-11.5M | $-15.4M | $-0.14 | — |
| Q2 2025 | $10.0M | 54.4% | $-11.4M | $-13.5M | $-0.14 | — |
| Q1 2025 | $8.7M | 58.1% | $-19.4M | $-22.9M | $-0.24 | — |
| Q4 2024 | $11.9M | 61.9% | $-13.6M | $-17.1M | $-0.19 | — |
| FY 2024 | $57.6M | 69.0% | $-30.8M | $-44.1M | $-0.51 | — |
| Q3 2024 | $13.5M | 67.2% | $-8.3M | $-11.5M | $-0.13 | — |
| Q2 2024 | $20.1M | 77.5% | $55.0K | $-2.7M | $-0.03 | — |
| Q1 2024 | $12.1M | 63.6% | $-9.0M | $-12.8M | $-0.17 | — |
| Q4 2023 | $13.2M | 64.6% | $-3.9M | $-8.1M | $-0.12 | — |
| FY 2023 | $50.6M | 58.8% | $-15.1M | $-7.9M | $-0.13 | — |